Pharma major Dr Reddy’s Laboratories has launched Clopidogrel tablets in the US market with 180-days exclusivity.
The tablets are a bioequivalent generic version of Plavix of Bristol Myers Squibb and Sanofi SA, a blood thinner drug.
The Hyderabad-based company was among the first applicants to submit a substantially complete Abbreviated New Drug Application for Clopidogrel tablets in 300 mg capacity and was awarded 180 days of marketing exclusivity, according to a release.
The Plavix brand had US sales of approximately $6.740 billion for the most recent 12 months ended March 31, 2012, according to IMS Health.